Financial Performance - Revenue for the first half of 2024 was RMB 299.4 million, an increase of 11.55% compared to the same period last year[11] - Net profit attributable to shareholders of the listed company was RMB 56.7 million, a decrease of 38.13% year-on-year[11] - Net cash flow from operating activities was RMB 35.48 million, down 42.07% compared to the same period last year[11] - Basic earnings per share were RMB 0.4735, a decrease of 37.99% year-on-year[11] - Total assets at the end of the reporting period were RMB 2.88 billion, an increase of 2.21% compared to the end of the previous year[11] - The weighted average return on equity was 2.18%, down 1.34 percentage points from the same period last year[11] - The company achieved revenue of RMB 299.40 million, a year-on-year increase of 11.55%[16] - Net profit attributable to shareholders of the listed company was RMB 56.70 million[16] - Total operating revenue for the first half of 2024 reached 299.4 million yuan, an increase of 11.6% compared to 268.4 million yuan in the same period of 2023[128] - Operating costs for the first half of 2024 were 222.9 million yuan, a significant rise of 36.7% from 163.0 million yuan in the first half of 2023[128] - R&D expenses increased to 78.2 million yuan in the first half of 2024, up 29.1% from 60.6 million yuan in the same period of 2023[128] - Net profit attributable to parent company shareholders was 56.7 million yuan in the first half of 2024, a decrease of 38.1% compared to 91.6 million yuan in the first half of 2023[129] - Basic earnings per share for the first half of 2024 were 0.4735 yuan, down 38.0% from 0.7636 yuan in the same period of 2023[129] - Parent company's operating income for the first half of 2024 was 218.1 million yuan, a 4.2% decrease from 227.6 million yuan in the first half of 2023[131] - Parent company's R&D expenses grew to 66.0 million yuan in the first half of 2024, a 33.5% increase from 49.4 million yuan in the same period of 2023[131] - Parent company's net profit for the first half of 2024 was 63.5 million yuan, a 46.3% decline from 118.1 million yuan in the first half of 2023[131] - Sales of goods and services received cash of 299,422,210.04 yuan in the first half of 2024, an increase from 264,403,158.42 yuan in the same period of 2023[133] - Total cash inflow from operating activities was 316,614,164.20 yuan in the first half of 2024, compared to 280,909,682.72 yuan in the first half of 2023[133] - Cash paid for goods and services increased to 36,650,476.80 yuan in the first half of 2024 from 21,712,616.47 yuan in the first half of 2023[133] - Cash paid to employees and for employee benefits rose to 143,989,988.90 yuan in the first half of 2024 from 114,609,175.99 yuan in the first half of 2023[133] - Net cash flow from operating activities decreased to 35,484,559.78 yuan in the first half of 2024 from 61,257,368.12 yuan in the first half of 2023[134] - Cash received from investment returns was 555,183,234.52 yuan in the first half of 2024, down from 833,088,891.50 yuan in the first half of 2023[134] - Cash paid for investments was 613,377,927.52 yuan in the first half of 2024, compared to 762,772,979.17 yuan in the first half of 2023[134] - Net cash flow from financing activities was 14,167,757.69 yuan in the first half of 2024, a significant improvement from -130,447,063.52 yuan in the first half of 2023[134] - The ending balance of cash and cash equivalents was 254,842,839.45 yuan at the end of the first half of 2024, down from 398,007,816.73 yuan at the end of the first half of 2023[134] - Cash received from sales of goods and services by the parent company was 246,714,660.02 yuan in the first half of 2024, up from 192,694,893.10 yuan in the first half of 2023[134] - Operating cash flow increased significantly to RMB 66.29 million, up from RMB 3.22 million in the previous period[135] - Investment cash flow showed a net outflow of RMB 146.54 million, compared to a net inflow of RMB 65.86 million in the previous period[135] - Financing cash flow turned positive with a net inflow of RMB 19.76 million, reversing from a net outflow of RMB 129.34 million in the previous period[135] - Total cash and cash equivalents decreased by RMB 60.49 million, ending at RMB 134.40 million[135] - The company invested RMB 625.85 million in new investments, down from RMB 744.57 million in the previous period[135] - Revenue from equity investments was RMB 7.81 million, showing a decrease from the previous period[135] - The company paid RMB 107.75 million in dividends to shareholders[136] - Comprehensive income for the period was RMB 56.69 million[136] - Owner's equity decreased by RMB 48.66 million due to dividend payments and other factors[136] - The company allocated RMB 8.17 million for equity-based compensation[136] - The company's total owner's equity at the end of the period was 2,549,233,147.34 yuan, with a capital reserve of 2,106,234,863.27 yuan and retained earnings of 276,160,490.27 yuan[140] - The company's comprehensive income for the period was 98,926,686.94 yuan, with a net profit of 91,631,863.04 yuan[139] - The company allocated 120,000,000 yuan for profit distribution, including 120,000,000 yuan for shareholder dividends[139] - The company's capital reserve decreased by 33,531,298.23 yuan due to capital reserve transfer to share capital[139] - The company's total owner's equity at the beginning of the period was 2,568,707,079.64 yuan, with a capital reserve of 2,139,766,161.50 yuan and retained earnings of 304,528,627.23 yuan[138] - The company's total owner's equity at the end of the period was 2,776,348,891.60 yuan, with a capital reserve of 2,091,386,238.48 yuan and retained earnings of 516,270,237.78 yuan[141] - The company's total owner's equity decreased by 42,126,829.73 yuan during the period, with a decrease in retained earnings of 44,298,857.55 yuan[141] - Comprehensive income for the first half of 2024 reached 63,454,722 yuan[142] - Owner's capital injection and reduction amounted to 8,174,813.82 yuan, with a net increase of 2,172,027.82 yuan[142] - Profit distribution for the period was -107,753,580 yuan[142] - The ending balance for the period was 2,734,222,061.87 yuan, with a significant increase in capital reserve and retained earnings[143] - The company's total equity at the end of the period was 2,719,945,610.47 yuan, reflecting a capital reserve of 2,103,821,159.55 yuan[145] - The company's total share capital as of December 31, 2023, was 120,000,000 yuan[147] - The company's financial statements were approved by the board on August 29, 2024[147] - The company's financial reporting is based on the Chinese Accounting Standards and the guidelines of the China Securities Regulatory Commission[148] - The company has assessed its ability to continue as a going concern for the next 12 months and found no issues[149] - The company's accounting policies and estimates are in line with the actual production and operation characteristics, adhering to the relevant accounting standards[150] - The company's normal operating cycle is one year, and this semi-annual report is prepared on a semi-annual basis[153] - The company's functional currency is RMB, and overseas subsidiaries use the currency of their primary economic environment as their functional currency[154] - Significant receivables are defined as those exceeding 1% of total assets, and the same standard applies to other receivables, prepayments, and payables[155] - For significant investment cash flows, the threshold is set at 10% of total assets[155] - Subsidiaries are considered significant if their total assets, revenue, or profit exceed 10% of the group's total[155] - In business combinations, the company measures assets and liabilities at their book value for transactions under common control and at fair value for non-common control transactions[156][157] - Transaction costs related to business combinations are expensed as incurred, except for costs related to issuing equity or debt securities, which are capitalized[159] - The company determines control based on power over the investee, exposure to variable returns, and the ability to influence returns[160] - If the parent company is an investment entity, only subsidiaries providing services related to investment activities are consolidated[161] - The company prepares consolidated financial statements by combining the financial statements of the parent and subsidiaries, eliminating intercompany transactions, and adjusting for special transactions[162] - Subsidiaries holding long-term equity investments in the company are treated as treasury stock and deducted from owner's equity in the consolidated balance sheet[164] - Unrealized internal transaction profits from the company selling assets to subsidiaries are fully offset against "net profit attributable to owners of the parent company"[164] - When purchasing minority equity in subsidiaries, the difference between the new long-term equity investment and the share of net assets is adjusted to capital surplus[165] - In step-by-step acquisitions of subsidiary control, the difference between the investment cost and the share of net assets is adjusted to capital surplus[166] - Disposal of subsidiary equity without losing control results in adjustments to capital surplus based on the difference between the disposal price and the share of net assets[166] - Loss of control over a subsidiary leads to re-measurement of remaining equity at fair value, with differences recognized as investment income[166] - Minority shareholder capital increases dilute the parent company's equity, with adjustments made to capital surplus[168] - Joint ventures are accounted for using the equity method under long-term equity investment standards[170] - Cash equivalents are defined as short-term, highly liquid investments with minimal value fluctuation risk[171] - Foreign currency transactions are initially recorded using the spot exchange rate or an approximate rate[172] - Foreign currency monetary items are translated at the spot exchange rate on the balance sheet date, with exchange differences recognized in current period profit or loss[173] - Foreign currency financial statements are adjusted to align with the company's accounting policies and periods before translation[174] - Foreign currency financial statement translation differences are presented separately under "other comprehensive income" in the consolidated balance sheet[175] - Financial assets are classified into three categories based on business model and contractual cash flow characteristics: amortized cost, fair value through profit or loss, and fair value through other comprehensive income[177] - Financial liabilities are classified into three categories: fair value through profit or loss, loan commitments and financial guarantee contract liabilities, and amortized cost[179] - Financial assets measured at fair value through other comprehensive income have their fair value changes recognized in other comprehensive income until derecognition[177] - Financial liabilities designated at fair value through profit or loss have changes in fair value due to own credit risk recognized in other comprehensive income[179] - Loan commitments are subject to impairment losses based on expected credit loss models[179] - Financial guarantee contract liabilities are measured at the higher of the loss provision amount determined under financial instrument impairment principles and the initial recognition amount less cumulative amortization[179] - Financial assets measured at fair value through profit or loss have all fair value changes recognized in current period profit or loss[178] - Derivative financial instruments are initially measured at fair value on the contract date and subsequently measured at fair value, with positive fair value recognized as an asset and negative fair value as a liability[181] - The company measures expected credit losses for financial assets at amortized cost, debt investments at fair value with changes in other comprehensive income, contract assets, lease receivables, loan commitments, and financial guarantee contracts[182] - Expected credit loss is the weighted average of credit losses of financial instruments, weighted by the risk of default, and is calculated as the present value of the difference between all contractual cash flows receivable and all expected cash flows to be received[182] - Financial instruments are classified into three stages based on credit risk: Stage 1 (credit risk not significantly increased), Stage 2 (credit risk significantly increased but no credit impairment), and Stage 3 (credit impairment occurred)[182] - For financial instruments with low credit risk, the company assumes no significant increase in credit risk and measures loss provisions based on 12-month expected credit losses[182] - The company calculates expected credit losses for accounts receivable based on historical credit loss experience, current conditions, and future economic forecasts, using a table of aging and lifetime expected credit loss rates[183] - For debt investments and other debt investments, expected credit losses are calculated based on the nature of the investment, counterparty, and risk exposure types, using 12-month or lifetime expected credit loss rates[184] - A financial instrument is considered to have low credit risk if the borrower has a strong ability to meet contractual cash flow obligations in the short term, even under adverse economic conditions[184] - The company assesses whether credit risk has increased significantly by comparing the probability of default at the reporting date with the probability of default at initial recognition[184] - Financial assets are considered credit-impaired when observable events occur that have a negative impact on expected future cash flows, such as significant financial difficulties of the issuer or debtor, breach of contract, or bankruptcy[184] - The company re-measures expected credit losses at each balance sheet date, with changes in loss provisions recognized as impairment losses or gains in the current period's profit and loss[185] - Financial assets are written off when the company no longer reasonably expects to recover all or part of the contractual cash flows, with any subsequent recoveries recognized as a reversal of impairment losses[185] - Financial assets are derecognized when the company transfers substantially all risks and rewards, or when control is relinquished, with the difference between the carrying amount and the consideration received recognized in profit and loss[186] - The company continues to recognize transferred financial assets if it retains substantially all risks and rewards, with the consideration received recognized as a financial liability[187] - Financial assets and liabilities are presented separately in the balance sheet and are not offset unless specific conditions are met[188] - Fair value is determined based on the price in the principal market or the most advantageous market, using assumptions that maximize economic benefits[190] - The company uses valuation techniques such as market approach, income approach, and cost approach to determine fair value, prioritizing observable inputs[190] - Inventory is measured at the lower of cost or net realizable value, with impairment recognized when cost exceeds net realizable value[192] - The company uses the first-in, first-out (FIFO) method for inventory costing and maintains a perpetual inventory system with annual physical counts[191] - Impairment of inventory is generally assessed on an individual item basis, but for large quantities of low-value items, it is assessed by category[192] - The company determines the net realizable value of raw materials based on the estimated selling price of the finished products, minus the estimated costs to complete, selling expenses, and related taxes[193] - The net realizable value of semi-finished and finished products is determined based on inventory age[193] - Contract assets and liabilities are presented separately in the balance sheet, with net amounts shown as either contract assets or contract liabilities depending on the balance[194] - Contract costs are categorized into contract fulfillment costs and contract acquisition costs, with specific conditions for recognition as assets[195] - Assets related to contract costs are amortized based on the same basis as the recognition of revenue from the related goods or services[195] - Non-current assets or disposal groups held for sale are classified based on specific conditions, including the likelihood of sale within one year[197] - The initial measurement of non-current assets or disposal groups held for sale is based on the lower of their carrying amount or fair value minus costs to sell[198] - Termination of operations is defined as a component of the company that represents a separate major line of business or geographical area of operations[199] - The company separately presents assets and liabilities of disposal groups held for sale in the balance sheet, without offsetting[200] Dividend and Shareholder Information - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserve into share capital[2] - The company granted 640,000 second-class restricted shares to 87 initial incentive recipients at a price of 76 yuan per share on May 10, 2022[80] - The company adjusted the initial and reserved grant price from 76 yuan to 74.5 yuan per share and granted 160,000 reserved shares to 36 eligible recipients on May 8, 2023[80] - The company further adjusted the initial and reserved grant price to 48.67 yuan per share, increased the initial grant quantity from 640,000 to 960,000 shares, and increased the reserved grant quantity from 160,000 to 240,000 shares due to the completion of the 2022 annual equity distribution plan on June 7, 2023[81] - The company granted 1,308,970 second-class restricted shares to 137 initial incentive recipients at a price of 33.58 yuan per share on December 4, 2023[83] - The company repurchased 273,800 shares, representing 0.2282% of the total shares, with a total repurchase amount of 16,001,134.45 yuan[112] - The company's total share capital remained unchanged at 120,000,000 shares, with 44.14% being restricted shares and 55.86% being unrestricted shares[111

证券代码：301080 证券简称：百普赛斯 公告编号：2024-026 6、回购股份的数量及占公司总股本的比例：按回购资金总额上限人民币 4,000 万元和回购价格上限 50.00 元/股进行测算，预计回购股份数量为 800,000 股，约 占公司当前总股本的 0.67%；按回购资金总额下限人民币 2,000 万元和回购价格 上限 50.00 元/股进行测算，预计回购股份数量为 400,000 股，约占公司当前总股 本的 0.33%，具体回购股份的数量及占公司总股本的比例以回购结束时实际回购 的股份数量及占公司总股本的比例为准。 7、回购股份的实施期限：自公司股东大会审议通过本次回购股份方案之日起 12 个月内。 北京百普赛斯生物科技股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1、回购股份的种类：公司发行的人民币普通股（A 股）股票。 2、回购股份的资金来源：公司自有资金。 3、回购股份的用途：本次回购股份将用于注销并相应减少公司注册资本。 4、回购股份的资金总额：本次回购资金总额不低于人民币 2, ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据深圳证券交易所《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》的规定，将北京百普赛斯生物科技股份有限公司（以下简称"公 司"）2024 年半年度募集资金存放与使用情况报告如下： 北京百普赛斯生物科技股份有限公司 2024 年半年度募集资金存放与使用情况的专项报告 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监发行字会[2021]2824 号文《关于同意北京百 普赛斯生物科技股份有限公司首次公开发行股票注册的批复》核准，公司于 2021 年 10 月向社会公开发行人民币普通股（A 股）2,000.00 万股，每股发行价为 112.50 元，应募集资金总额为人民币 225,000.00 万元，根据有关规定扣除发行费用 15,575.92 万元后，实际募集资金金额为 209,424.08 万元。该募集资金已于 2021 年 10 月到账。上述资金到账情况业经容诚会计师事务所（特殊 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2024-021 北京百普赛斯生物科技股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京百普赛斯生物科技股份有限公司（以下简称"公司"）第二届董事会第八 次会议于 2024 年 8 月 29 日上午 10:00 在北京市北京经济技术开发区宏达北路 8 号公司会议室以通讯表决和现场表决的方式召开。本次会议通知及会议资料于 2024 年 8 月 19 日以专人送达、传真、电子邮件的方式发出，会议应出席董事 7 人，参与现场会议的董事 3 人，参与通讯会议的董事 4 人，分别为李杨女士、许 娟红女士、刘峰先生、张勇先生。会议由董事长陈宜顶先生主持，公司监事、高 级管理人员列席会议。会议的召集、召开符合法律、法规、规则和《公司章程》 规定。 二、董事会会议审议情况 参会的董事一致同意通过如下决议： （一）审议通过《关于公司<2024 年半年度报告全文及其摘要>的议案》 公司董事会认真审阅了《2024 年半年度报告》及其摘要，认为《2024 年半 ...

一、召开会议的基本情况 1、股东大会届次：北京百普赛斯生物科技股份有限公司（以下简称"公司"） 2024 年第一次临时股东大会。 2、股东大会的召集人：公司董事会。 3、会议召开的合法性、合规性：公司于 2024 年 8 月 29 日召开了第二届董 事会第八次会议，审议通过了《关于提请召开 2024 年第一次临时股东大会的议 案》。本次股东大会的召开符合有关法律、行政法规、部门规章、规范性文件、 深圳证券交易所规则和公司章程等的规定。 4、会议召开的日期、时间： 证券代码：301080 证券简称：百普赛斯 公告编号：2024-027 北京百普赛斯生物科技股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 6、会议的股权登记日：2024 年 9 月 12 日（星期四） 7、出席对象： （1）截至 2024 年 9 月 12 日下午 15:00 交易结束后，在中国证券登记结算 有限责任公司深圳分公司登记在册的持有公司已发行有表决权股份的全体股东。 上述公司全体股东均有权出席本次股东大会，并可以以书面形式委托 ...

北京百普赛斯生物科技股份有限公司 2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：北京百普赛斯生物科技股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公 | 上市公司核算的 | 2024年初占用资 | 2024年半年度占 | 2024年半年度占 用资金的利息(如 | 2024年半年度偿 | 2024年6月30日占 | | | | 非经营性资金占用 | 资金占用方名称 | 司的关联关系 | 会计科目 | 金余额 | 用累计发生金额 | | 还累计发生金额 | 用资金余额 | 占用形成原因 | 占用性质 | | | | | | | (不含利息) | 有) | | | | | | 控股股东、实际控制人及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小计 | — | — | — | | | | | | | | | 前控股股东、实际控制人 | | | ...

证券代码：301080 证券简称：百普赛斯 公告编号：2024-025 1、本次计提资产减值损失及信用减值损失的原因 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及北京百普赛 斯生物科技股份有限公司（以下简称"公司"或"本公司"）会计政策的相关规定， 为更加真实、准确地反映公司截至 2024 年 6 月 30 日的财务状况和经营成果，基 于谨慎性原则，公司对合并报表范围内的各类资产进行了全面清查，并进行了充 分的分析和评估，对可能发生减值损失的资产计提了减值准备。 2、资产减值损失及信用减值损失的计提情况 本次计提信用减值损失和资产减值损失的资产项目主要为应收账款、其他应 收款和存货。截至 2024 年 6 月 30 日，公司计提各项减值损失金额合计 1,870.94 万元。具体情况如下： 二、本次计提资产减值损失及信用减值损失的确认标准及计提方法 （1）金融工具减值 本公司对于以摊余成本计量的金融资产、以公允价值计量且其变动计入其他 综合收益的债权投资、合同资产、租赁应收款、贷款承诺及财务担保合同等，以 预期信用损失为基础 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2024-022 北京百普赛斯生物科技股份有限公司 第二届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 表决结果：3 票同意，0 票反对，0 票弃权。 （二）审议通过《关于公司<2024 年半年度募集资金存放与使用情况的专项 报告>的议案》 经审核，监事会认为： 二、监事会会议审议情况 参会的监事一致同意通过如下决议： （一）审议通过《关于公司<2024 年半年度报告全文及其摘要>的议案》 经审核，监事会认为： 董事会编制和审议公司《2024 年半年度报告》的程序符合法律、法规和中国 证监会的有关规定，报告内容真实、准确、完整地反映了公司的实际情况，不存 在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《2024 年半 年度报告》，以及在《中国证券报》《证券时报》《证券日报》《上海证券报》 及巨潮资讯网（www.cninfo.com.cn）披露的《2024 年半年度报告摘要》。 报告期内公司 ...

近日，公司完成了工商变更登记、《公司章程》备案等手续，并取得了北 京经济技术开发区市场监督管理局颁发的《营业执照》。其中市场监督管理局 更新并统一了企业经营范围术语，公司原经营范围表述须根据新术语做相应调 整，该差异对公司业务经营不产生实质影响。公司已对 2023 年 12 月 5 日在巨 潮资讯网（www.cninfo.com.cn）披露的《公司章程》中涉及经营范围的条款内 容作出相应调整，调整后的《公司章程》详见相关公告。相关信息如下： 名称：北京百普赛斯生物科技股份有限公司 证券代码：301080 证券简称：百普赛斯 公告编号：2024-020 北京百普赛斯生物科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）分别于 2023 年 12 月 4 日、2023 年 12 月 20 日召开第二届董事会第五次会议、2023 年第三次临时 股东大会，审议通过了《关于变更公司经营范围暨修订<公司章程>的议案》，具 体内容详见公司在巨潮资讯网（www.cni ...

北京百普赛斯生物科技股份有限公司 章程 二〇二四年七月 | 第一章 | | 总则 | 1 | | --- | --- | --- | --- | | 第二章 | | 经营宗旨和范围 | 2 | | 第三章 | 股 | 份 | 3 | | 第一节 | | 股份发行 | 3 | | 第二节 | | 股份增减和回购 | 5 | | 第三节 | | 股份转让 | 6 | | 第四章 | | 股东和股东大会 | 7 | | 第一节 | | 股东 | 8 | | 第二节 | | 股东大会的一般规定 | 10 | | 第三节 | | 股东大会的召集 | 17 | | 第四节 | | 股东大会的提案与通知 | 18 | | 第五节 | | 股东大会的召开 | 20 | | 第六节 | | 股东大会的表决和决议 | 24 | | 第五章 | | 董事会 | 28 | | 第一节 | | 董事 | 28 | | 第二节 | | 董事会 | 32 | | 第六章 | | 总经理及其他高级管理人员 | 38 | | 第七章 | | 监事会 | 40 | | 第一节 | | 监事 | 40 | | 第二节 | | 监事会 | 41 | ...